Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Burden

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
BMJ Open|March 31, 2021
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareSiew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, et al.
The American Journal of Pathology|August 8, 2012
Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasisMark D Singh, Vicky King, Helen Baldwin, et al.
American Journal of Human Genetics|August 16, 2011
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasisAlexandros Onoufriadis, Michael A Simpson, Andrew E Pink, et al.
The British Journal of Dermatology|July 17, 2025
Mendelian randomization identifies OX40 as a potential mediator of the effects of cigarette smoking in palmoplantar pustulosisAlice Smail, Nick Dand, Xinyue Liu, et al.
The Journal of Investigative Dermatology|August 22, 2018
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort StudyNina Wilkinson, Teresa Tsakok, Nick Dand, et al.
The Journal of Investigative Dermatology|May 2, 2017
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-AnalysisZarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, et al.
The Journal of Investigative Dermatology|September 21, 2019
IL-36 Promotes Systemic IFN-I Responses in Severe Forms of PsoriasisMarika Catapano, Marta Vergnano, Marco Romano, et al.
The Journal of Investigative Dermatology|September 3, 2017
Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-AnalysisZarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, et al.
The British Journal of Dermatology|April 19, 2023
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activityA David Burden, Hervé Bachelez, Siew Eng Choon, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
BMJ Open|March 31, 2021
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flareSiew Eng Choon, Mark G Lebwohl, Slaheddine Marrakchi, et al.
The American Journal of Pathology|August 8, 2012
Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasisMark D Singh, Vicky King, Helen Baldwin, et al.
American Journal of Human Genetics|August 16, 2011
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasisAlexandros Onoufriadis, Michael A Simpson, Andrew E Pink, et al.
The British Journal of Dermatology|July 17, 2025
Mendelian randomization identifies OX40 as a potential mediator of the effects of cigarette smoking in palmoplantar pustulosisAlice Smail, Nick Dand, Xinyue Liu, et al.
The Journal of Investigative Dermatology|August 22, 2018
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort StudyNina Wilkinson, Teresa Tsakok, Nick Dand, et al.
The Journal of Investigative Dermatology|May 2, 2017
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-AnalysisZarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, et al.
The Journal of Investigative Dermatology|September 21, 2019
IL-36 Promotes Systemic IFN-I Responses in Severe Forms of PsoriasisMarika Catapano, Marta Vergnano, Marco Romano, et al.
The Journal of Investigative Dermatology|September 3, 2017
Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-AnalysisZarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, et al.
The British Journal of Dermatology|April 19, 2023
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activityA David Burden, Hervé Bachelez, Siew Eng Choon, et al.
Pageof 9